Golf Pro Struck by Mysterious Illness After COVID-Now Wheelchair-Bound and Unable to Walk

A 47-year-old Hamburg golf instructor, David Entwistle, has become one of the first documented cases of post-viral autoimmune neuropathy following a mild COVID-19 infection in 2023, leaving him permanently wheelchair-bound despite no prior medical history. His case—now under investigation by the German Society for Neurology (DGN)—highlights an emerging clinical pattern linking SARS-CoV-2 to autoimmune demyelination, a condition where the immune system attacks peripheral nerves, mimicking Guillain-Barré syndrome but with irreversible progression.

Key Clinical Takeaways:

• Post-viral autoimmune neuropathy may affect up to 1 in 10,000 COVID-19 patients, per a 2025 JAMA Neurology meta-analysis, though most cases resolve within 6 months—Entwistle’s is one of 12 confirmed chronic cases in Germany.
• Diagnosis relies on nerve conduction studies and CSF analysis for oligoclonal bands; Entwistle’s results showed 92% axonal loss in the sciatic nerve, a severity rarely documented in post-viral neuropathy.
• No FDA/EMA-approved treatment exists, but high-dose IV immunoglobulin (IVIG) and rituximab (a B-cell depleting monoclonal antibody) show promise in early-phase trials, funded by the German Federal Ministry of Health.

Why Is This Case Unusual?

Entwistle’s rapid decline—from walking 18 holes daily to requiring a wheelchair within three months—challenges the prevailing assumption that post-COVID neuropathy is primarily inflammatory and reversible. His symptoms align with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder typically triggered by infections or vaccines. However, unlike classic CIDP, Entwistle’s condition progressed despite two rounds of IVIG therapy, suggesting a distinct SARS-CoV-2-specific autoimmune pathway.

“We’re seeing a subset of patients where the virus doesn’t just cause temporary inflammation—it appears to reprogram immune memory,” said Dr. Anja Steiner, a neurologist at the University Hospital Hamburg-Eppendorf and lead investigator on the case. “Entwistle’s autoantibodies target myelin-associated glycoprotein (MAG), a protein not typically implicated in post-viral neuropathy. This could explain why standard treatments fail.”

“This isn’t just another long-COVID story. We’re dealing with a de novo autoimmune disease that may require entirely new therapeutic strategies.”

How Common Is This Link Between COVID-19 and Autoimmune Neuropathy?

While Entwistle’s case is extreme, it reflects growing evidence from three large-scale studies published since 2024:

The DGN registry—the most comprehensive to date—identifies 17 similar cases in Germany alone, with Entwistle’s being the first to achieve permanent disability. The discrepancy in chronic progression rates (ranging from 0.5% to 2.1%) may stem from underreporting in outpatient settings, where milder cases are less likely to be documented.

What’s the Biological Mechanism?

Researchers hypothesize that SARS-CoV-2’s spike protein may trigger molecular mimicry, where the immune system confuses viral antigens with self-proteins in peripheral nerves. A preprint study from the University of Hamburg’s Neuroimmunology Lab (not yet peer-reviewed) found that 68% of Entwistle’s autoantibodies cross-reacted with myelin basic protein (MBP), a key target in multiple sclerosis.

“This suggests a shared autoimmune pathway between COVID-19 and demyelinating diseases,” said Dr. Steiner. “However, unlike MS, these patients don’t have the typical CNS lesions—only peripheral nerve damage. That’s why existing MS therapies like ocrelizumab haven’t worked for Entwistle.”

What Treatment Options Exist—and Why Aren’t They Working?

Entwistle underwent two rounds of IVIG (2g/kg over 5 days) and plasma exchange, both standard for CIDP, with no improvement. His case now falls under an EMA-approved compassionate-use protocol for rituximab, a B-cell depleting therapy used in rheumatoid arthritis. Early results from a Phase II trial (N=45) funded by the German Federal Ministry of Health show 40% partial remission in post-COVID CIDP patients after 12 weeks.

However, no treatment has been approved specifically for post-viral autoimmune neuropathy. The closest analog is siponimod, a sphingosine-1-phosphate receptor modulator approved for secondary progressive MS, which is being tested in a single-arm trial at the Charité Berlin (N=20, expected results in Q4 2026).

How Are Clinics Adapting to This Emerging Threat?

Hospitals in Germany are establishing post-COVID neuroimmunology clinics to centralize care. The University Medical Center Hamburg-Eppendorf, where Entwistle is treated, now offers:

• Advanced nerve conduction studies with quantitative sensory testing to detect early demyelination.
• Autoantibody profiling via Mayo Clinic Labs’ expanded panel, which now includes MAG and neurofascin-155—markers linked to post-viral neuropathy.
• Multidisciplinary boards combining neurologists, rheumatologists, and infectious disease specialists to rule out other causes (e.g., B12 deficiency, diabetic neuropathy, or Lyme disease).

For patients like Entwistle, physical and occupational therapy remain critical. The German Society for Rehabilitation Medicine (DGRM) reports that 60% of post-COVID neuropathy patients who combine therapy with early immunotherapy achieve functional independence within 18 months.

What’s Next for Research—and How Can Patients Access Care?

The EMA is reviewing rituximab’s expanded use for post-viral CIDP, with a decision expected by March 2027. Meanwhile, the DGN has launched a patient registry to track long-term outcomes, with 500+ enrollments since January 2026.

Patients experiencing progressive weakness, numbness, or tingling after COVID-19 should seek evaluation at specialized centers. In Germany, the following resources are available:

• Board-certified neuroimmunologists with experience in post-viral CIDP (e.g., University Medical Center Hamburg-Eppendorf).
• Autoimmune disease clinics offering autoantibody testing (e.g., Charité Berlin’s Neuroimmunology Unit).
• Healthcare compliance attorneys specializing in long-COVID disability claims, as 42% of chronic cases in the DGN registry qualify for long-term disability benefits.

The trajectory of this research will hinge on whether post-viral neuropathy is a distinct entity or a variant of existing autoimmune diseases. If the latter, repurposed therapies like ofatumumab (a newer anti-CD20) may offer hope. If the former, entirely new nerve-protective biologics will be needed—a race that could take 5–10 years.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.